exosom
propos
candid
therapeut
immun
present
studi
demonstr
incorpor
g
protein
vesicular
stomat
viru
vsvg
exosomelik
vesicl
elv
enhanc
uptak
induc
matur
dendrit
cell
target
vsvg
ovalbumin
model
antigen
elv
increas
crosspresent
ovalbumin
via
endosom
acidif
mechan
immun
mice
vsvg
ovalbumin
contain
elv
led
increas
antibodi
respons
expans
antigenspecif
cell
strong
vivo
ctl
respons
protect
challeng
ovalbumin
express
tumor
cell
thu
incorpor
vsvg
target
antigen
elv
attract
strategi
improv
exosom
vaccin
exosom
releas
dendrit
cell
dc
cancer
cell
propos
vaccin
candid
immunotherapi
tumor
aris
multivesicular
bodi
exosom
contain
restrict
set
cellular
protein
exosom
hallmark
protein
heat
shock
protein
tetraspanin
modul
dc
activ
lead
improv
immunogen
efficaci
exosomebas
cancer
vaccin
although
exosom
releas
cancer
cell
constitut
contain
tumor
antigen
process
protein
sort
vesicl
within
multivesicular
bodi
still
remain
unclear
poor
result
clinic
trial
also
rais
concern
regard
efficaci
exosomalbas
cancer
vaccin
suggest
new
approach
improv
efficaci
exosomebas
vaccin
warrant
direct
target
protein
antigen
exosom
might
improv
specif
exosom
vaccin
one
possibl
strategi
exogen
load
mhci
molecul
dcderiv
exosom
peptid
report
recent
demonstr
replac
transmembran
cytoplasm
domain
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
protein
g
protein
vesicular
stomat
viru
vsvg
result
enhanc
shed
protein
vesicleassoci
form
supernat
transfect
cell
presenc
protein
indic
exosomelik
natur
vesicl
viral
fusion
protein
might
provid
attract
strategi
enhanc
uptak
exosom
vaccin
profession
antigen
present
cell
thu
improv
immunogen
sinc
transmembran
intracytoplasm
domain
vsvg
suffici
tether
heterolog
protein
exosomelik
vesicl
elv
vsvg
also
incorpor
elv
g
protein
vsv
type
transmembran
glycoprotein
kda
size
compos
ectodomain
membran
span
domain
cytoplasm
domain
vsvg
protein
mediat
attach
viral
particl
cell
membran
induc
fusion
viral
envelop
target
cell
ph
buseyn
et
al
demonstr
incorpor
fusioncompet
vsvg
hivbas
viral
vector
lead
effici
uptak
particl
immatur
dc
present
gagderiv
peptid
mhci
molecul
furthermor
vsvg
shown
enhanc
immunogen
hivgag
dna
vaccin
coexpress
antigen
also
previous
demonstr
incorpor
fusioncompet
fusiondefici
vsvg
virallik
particl
vlp
vaccin
led
increas
antibodi
titer
hivgag
protein
vlp
given
immunostimulatori
properti
vsvg
incorpor
elv
potenti
could
increas
immunogen
exosomebas
vaccin
present
studi
analyz
effect
vsvg
elvuptak
dc
dcfunction
character
immun
respons
elvassoci
antigen
purpos
tether
model
antigen
ovalbumin
ova
elv
fuse
ova
protein
transmembran
intracytoplasm
domain
vsvg
incorpor
vsvg
elv
provid
enhanc
uptak
vesicl
present
exosom
antigen
dc
well
phenotyp
function
dc
matur
vitro
furthermor
vivo
studi
demonstr
effici
induct
antigenspecif
ctl
respons
thu
target
antigen
viral
fusion
protein
elv
improv
immunogen
exosom
vaccin
human
embryon
kidney
cell
deriv
cell
quantum
biotechnolog
montreal
canada
mous
melanoma
cell
line
maintain
dmem
supplement
fc
lglutamin
penicillin
streptomycin
plasmid
purchas
clontech
heidelberg
germani
construct
vcg
bh
hgpsyn
pcdg
syn
describ
construct
pcdg
mut
glutamin
asparagin
point
mutat
introduc
posit
codonoptim
vsvg
gene
describ
wild
type
vsvg
construct
express
plasmid
membranebound
ova
protein
ova
gene
amplifi
use
forward
primer
agctggctagcaagcttccaccatgaagtgcctgctgtacctggccttcctgt
tcatcggcgtgaactgcggatccatgggctccatcgg
cgcagcaagcatgga
contain
vsvg
leader
sequenc
flank
nhei
hindiii
restrict
enzym
revers
primer
ggatccagcgctaggggaaacacatctgccaaagaa
gag
flank
bamhi
restrict
enzym
transmembran
domain
amplifi
plasmid
pcdg
syn
use
forward
primer
tctcttctttggcagatgtgtttcccctagcgctggatccttcggcgacaccggcctga
gcaagaac
revers
primer
ctgcagaattctt
atcacttgcccagcctg
flank
ecori
restrict
site
product
purifi
use
pcr
purif
kit
qiagen
oldenburg
germani
mix
use
templat
subsequ
pcr
use
primer
result
pcr
fragment
clone
nheiecori
digest
plasmid
invitrogen
karlsruh
germani
gener
pexova
dna
prepar
immun
elv
product
perform
use
endofre
plasmid
prepar
kit
qiagen
semiconflu
cell
monolay
transfect
cm
tissu
cultur
flask
g
pexova
alon
togeth
g
pcdg
syn
pcdg
mut
produc
oelv
oelvg
oelvg
mut
vesicl
respect
product
elvg
elvg
mut
vesicl
g
pcdgsyn
pcdgmut
transfect
togeth
g
carrier
dna
invitrogen
eight
hour
transfect
fcscontain
medium
chang
serumfre
medium
invitrogen
condit
medium
harvest
h
later
elv
concentr
ultracentrifug
sucros
cushion
describ
previous
step
gradient
ultracentrifug
pellet
elv
resuspend
pb
load
onto
sucros
gradient
contain
sucros
centrifug
h
rpm
result
protein
fraction
concentr
fourfold
use
mw
cutoff
vivaspin
filter
determin
ova
vsvg
content
elv
elisa
assay
perform
use
solubl
ova
protein
vsvg
peptid
sigmaaldrich
tauchkirchen
germani
standard
serial
dilut
elv
prepar
standard
proteinspeptid
incub
overnight
c
block
fatfre
milk
h
room
temperatur
primari
antibodi
rabbit
antiova
biodesign
intern
saco
main
mous
antivsvg
sigmaaldrich
use
secondari
hrpconjug
antibodi
stabil
tmb
chromogen
obtain
dako
hamburg
germani
total
protein
concentr
elv
determin
biorad
protein
assay
endotoxin
level
chromogen
lal
endpoint
assay
cambrex
germani
accord
manufactur
instruct
residu
dsdna
doubl
strain
dna
elv
prepar
measur
qubit
quantit
platform
invitrogen
accord
manufactur
instruct
western
blot
analysi
perform
describ
previous
blot
incub
rabbit
antiova
mous
antivsvg
antiserum
sigmaaldrich
mous
antibodi
santa
cruz
biotechnolog
inc
heidelberg
germani
thereaft
goat
antirabbit
rabbit
antimous
hrpconjug
antiserum
use
sigmaaldrich
protein
band
detect
western
blot
detect
kit
biozym
scientif
gmbh
oldendorf
germani
accord
manufactur
instruct
cell
transfect
pexova
psolova
describ
surfac
stain
rabbit
antiova
fitcconjug
antirabbit
igg
ab
use
express
analysi
perform
describ
cell
transfect
either
pcdg
syn
pcdg
mut
presenc
two
day
transfect
cell
incub
min
vsvg
fusion
buffer
mm
me
mm
hepe
ph
pb
remov
fusion
buffer
cell
incub
h
c
fresh
dmem
media
syncytia
format
monitor
fluoresc
microscop
cell
transfect
vcg
bh
sgpsyn
either
pcdg
syn
pcdg
mut
experi
perform
describ
ref
titrat
cell
use
gfpposit
cell
count
fluoresc
microscop
vector
titer
calcul
number
gfpposit
cellswel
mice
hous
anim
facil
faculti
medicin
ruhr
univers
bochum
germani
handl
accord
feder
european
laboratori
anim
scienc
associ
sixto
mice
charl
river
wiga
gmbh
sulzfeld
germani
use
tcrtransgen
mice
purchas
jackson
laboratori
bar
harbor
usa
purif
dc
singl
cell
suspens
mice
splenocyt
prepar
previous
describ
dc
enrich
posit
select
magnet
bead
miltenyi
biotec
gmbh
germani
accord
manufactur
instruct
result
cell
routin
pure
cell
tcrtransgen
mice
purifi
singl
cell
splenocyt
suspens
neg
select
use
magnet
bead
cell
isol
kit
miltenyi
biotec
vitro
prolifer
assay
cell
label
cfda
vybrant
cfda
cell
tracer
kit
molecular
probesinvitrogen
accord
manufactur
instruct
elv
label
cfda
h
room
temperatur
label
elv
dialyz
nacl
overnight
c
dc
incub
g
total
protein
content
elv
min
either
c
ice
control
gml
fitcdextran
fitcdx
ad
select
time
point
cell
collect
wash
three
time
icecold
medium
incub
first
fcblock
stain
antibodi
fluoresc
neg
cell
measur
flow
cytometri
dc
seed
densiti
cellswel
plate
incub
gml
elv
gml
lp
e
coli
sigmaaldrich
posit
control
condit
media
cultur
cell
harvest
h
later
determin
product
use
commerci
avail
elisa
kit
biosourc
europ
sa
nivel
belgium
accord
manufactur
instruct
cell
collect
stain
antimhc
ii
antibodi
bd
pharmingen
heidelberg
germani
analyz
level
cell
surfac
marker
flow
cytometri
dc
plate
flatbottom
plate
densiti
cellswel
incub
differ
concentr
sova
elv
prepar
h
c
intens
wash
prewarm
medium
cell
transfer
ubottom
plate
total
pool
cfdalabel
cell
spleen
mice
ad
well
incub
h
c
thereaft
cell
incub
apcconjug
b
ova
tetram
sanquin
reagent
amsterdam
netherland
prolifer
prime
ovaspecif
tetram
cell
assess
flow
cytometr
analysi
cfda
fluoresc
intens
label
cell
dc
first
incub
h
c
either
gml
brefeldin
lactacystin
nm
ammonium
chlorid
puls
thereaft
h
gml
sova
gml
ova
gml
oelvg
presenc
drug
cell
wash
cocultur
cfdalabel
cell
describ
mice
n
mice
per
group
immun
subcutan
twice
week
g
elv
oelv
oelvg
oelvg
mut
control
group
immun
either
g
solubl
ova
g
plasmid
dna
psolova
challeng
experi
cell
inocul
right
flank
mice
volum
tumor
determin
everi
day
mice
sacrif
volum
reach
mm
one
week
second
immun
mice
bled
antiova
antibodi
product
determin
elisa
briefli
flatbottom
plate
coat
overnight
g
ova
sigmaaldrich
block
fatfre
milk
incub
dilut
mice
serum
detect
ova
antibodi
respect
correspond
hrpconjug
secondari
antibodi
obtain
sigmaaldrich
ctl
assay
perform
describ
previous
use
gml
ova
peptid
prime
cfda
hi
cell
donor
cell
prepar
transfer
recipi
mice
day
second
immun
h
recipi
mice
euthan
spleen
lymph
node
obtain
cfda
hi
cfda
lo
popul
identifi
flow
cytometri
percent
specif
lysi
calcul
use
follow
formula
percent
specif
lysi
ratio
vaccinatedratio
control
ratio
percent
cfda
hi
percent
cfda
lo
determin
tcrposit
cell
spleen
cell
incub
subsequ
apcconjug
b
ova
tetram
antibodi
analyz
flow
cytometri
statist
analys
perform
use
graphpad
prism
softwar
inc
san
diego
ca
usa
comparison
differ
experiment
group
oneway
anova
analysi
perform
differ
consid
signific
p
order
target
antigen
exosom
fuse
open
read
frame
ova
nterminu
transmembran
cytoplasm
domain
vsvg
fig
addit
sequenc
code
leader
peptid
vsvg
protein
clone
frame
upstream
ova
cdna
result
plasmid
pexova
fac
analysi
cell
transient
transfect
pexova
reveal
presenc
ova
protein
cell
surfac
contrast
cell
transfect
psolova
encod
secret
ova
fig
fusiondefect
mutant
vsvg
construct
introduct
singl
qton
point
mutat
posit
codonoptim
vsvg
express
plasmid
previous
report
wild
type
vsvg
express
recombin
mutant
protein
vsvg
mut
confirm
western
blot
analysi
fig
lowph
fusion
buffer
cell
express
vsvg
form
larg
syncytia
easili
detect
vsvg
cotransfect
gfp
express
plasmid
fig
right
contrast
cell
transfect
express
plasmid
encod
vsvg
mut
show
detect
syncytia
fig
middl
indic
loss
fusion
activ
furthermor
lentivir
vector
pseudotyp
assay
also
perform
lentivir
vector
pseudotyp
vsvg
reach
titer
infecti
unitsml
pseudotyp
fusiondefect
mutant
reduc
titer
background
level
infecti
unitsml
data
shown
transient
transfect
cell
pexova
psolova
show
ova
readili
detect
lysat
cell
transfect
plasmid
fig
could
pellet
ultracentrifug
supernat
pexovatransfect
cell
suggest
associ
cellular
vesicl
fig
addit
expect
kda
ova
band
western
blot
analysi
addit
band
kda
observ
pexovatransfect
cell
probabl
repres
proteolyt
cleavag
product
chimer
ova
protein
fig
ultracentrifug
supernat
pexovatransfect
cell
sucros
step
gradient
reveal
ova
protein
detect
gradient
fraction
fig
upper
panel
also
contain
exosom
marker
protein
fig
lower
panel
indic
compar
densiti
distribut
exosom
ova
contain
vesicl
consist
exosom
local
chimer
ova
protein
experi
elv
prepar
supernat
transfect
cell
pellet
sucros
cushion
transfect
differ
vsvg
andor
ova
express
plasmid
result
variou
elv
tabl
con
exosomelik
vesicl
prepar
use
studi
transfect
plasmid
pcdgsyn
pcdgmut
pexova
cell
cotransfect
mark
plasmid
centrat
ova
vsvg
differ
elv
prepar
determin
elisa
mean
endotoxin
level
euml
exclud
potenti
effect
low
level
endotoxin
exosom
prepar
equal
endotoxin
concentr
compar
side
side
bind
subsequ
intern
particul
antigen
dc
may
initi
event
result
cascad
signal
transduct
cellular
activ
first
explor
effici
differ
elv
contain
fusioncompet
vsvg
fusiondefect
mutant
irrelev
nonvir
protein
ova
taken
dc
vitro
elv
label
carboxyfluorescein
diacet
cfda
dye
becom
highli
fluoresc
upon
intern
fitcdextran
use
posit
control
standard
data
sever
experi
consid
background
fluoresc
uptak
index
calcul
ratio
fluoresc
intens
cell
incub
c
cell
incub
ice
compar
oelv
elvg
mut
elvg
show
consist
signific
higher
level
uptak
dc
exposur
time
min
fig
contrast
uptak
index
splenocyt
fitcdx
elv
type
level
slightli
background
fig
consist
lower
uptak
activ
cell
thu
incorpor
vsvg
elv
significantli
increas
intern
dc
matur
dc
antigen
intern
next
step
requir
stimul
cell
respons
therefor
freshli
isol
splenic
dc
incub
elvg
elvg
mut
oelv
express
dc
activ
marker
determin
character
phenotyp
dc
matur
induc
elv
elvg
concentr
g
total
proteinml
g
lpsml
posit
control
led
similar
dc
matur
assess
control
elv
oelv
elvg
mut
show
lower
level
upregul
could
reflect
gener
elv
featur
fig
observ
effect
dosedepend
becam
undetect
elv
concentr
gml
data
shown
induct
effect
cell
respons
product
secret
cytokin
function
matur
dc
critic
dc
incub
elvg
secret
similar
high
level
dc
stimul
lp
hand
low
level
detect
supernat
untreat
dc
expos
oelv
elvg
mut
fig
final
endotoxin
concentr
cultur
medium
level
variou
experiment
elv
group
exceed
euml
addit
residu
amount
dsdna
elv
prepar
correl
dc
matur
level
highest
level
cultur
medium
ngml
reach
elvg
mut
group
thu
neither
lp
residu
plasmid
dna
explain
strong
dc
matur
effect
elvg
dendrit
cell
known
main
cell
type
abl
present
exogen
deriv
peptid
context
mhc
class
molecul
cell
sinc
vsvg
increas
uptak
elv
stimul
dc
matur
might
also
improv
subsequ
activ
antigenspecif
mhc
class
irestrict
cell
oelv
oelvg
mut
enhanc
prolifer
tcrtransgen
cell
specif
immunodomin
ova
epitop
ova
comparison
amount
solubl
ova
fig
elvg
final
concentr
g
ovaml
compar
obtain
puls
dc
gml
solubl
ova
fig
b
respect
importantli
prepar
elvg
oelv
separ
transfect
mix
prior
incub
dc
show
stimulatori
effect
similarli
mix
solubl
ova
elvg
enhanc
cell
prolifer
either
fig
indic
coloc
fusioncompet
vsvg
protein
antigen
interest
elv
necessari
enhanc
crosspresent
process
intern
protein
antigen
occur
either
proteasom
degrad
load
onto
mhci
tapdepend
manner
classic
mhci
pathway
altern
pathway
endolysosom
phagosom
process
pathway
oelvg
dc
examin
use
variou
inhibitor
brefeldin
use
inhibitor
exocytosi
lactacystin
irrevers
proteasom
inhibitor
ammonium
chlorid
inhibitor
endosom
acidif
also
delay
endosomallysosom
matur
process
k
b
restrict
ova
report
proteasomedepend
determin
activ
cell
hybridoma
express
cell
surfac
ova
mhc
class
complex
experi
pretreat
dc
lactacystin
inhibit
present
ova
peptid
deriv
solubl
ova
howev
drug
abrog
prolifer
cell
ova
taken
dc
oelvg
fig
contrast
ammonium
chlorid
strongli
inhibit
crosspresent
oelvg
even
low
dose
nm
absolut
ineffect
solubl
ova
fig
bfa
dramat
block
prolifer
specif
cell
case
fig
present
exogen
ova
peptid
requir
process
affect
treatment
could
serv
intern
control
prolif
featur
cell
data
shown
therefor
conclud
dc
process
elv
contain
fusioncompet
vsvg
degrad
mechan
involv
endosom
acidif
classic
proteasom
degrad
pathway
seem
main
sourc
immunodomin
peptid
load
onto
mhc
class
molecul
immunogen
elv
contain
fusioncompet
vsvg
compar
mice
immunogen
elv
lack
vsvg
elv
contain
fusiondefect
vsvg
order
correl
vitro
find
vivo
situat
addit
mice
also
receiv
standard
dna
vaccin
encod
solubl
ova
abl
compar
immunogen
exosom
vaccin
vaccin
strategi
mice
immun
odna
exhibit
high
serum
level
antiova
antibodi
subclass
fig
elv
immun
preferenti
induc
antiova
respons
fig
wherea
solubl
ova
induc
predomin
antibodi
respons
fig
incorpor
fusioncompet
vsvg
elv
select
enhanc
antibodi
level
fig
ovalbuminspecif
cellular
immun
respons
assess
fluoresc
tetramerbind
vivo
cytotox
tlymphocyt
ctl
assay
odna
vaccin
induc
moder
level
tetram
cell
fig
solubl
ova
protein
immun
lead
agspecif
cell
level
exceed
background
howev
immun
ova
context
elv
number
tetram
cell
compar
odna
group
incorpor
vsvg
increas
level
agspecif
cell
fig
agspecif
cell
observ
elv
immun
also
function
activ
strongest
specif
lysi
vivo
ctl
assay
obtain
mice
immun
oelvg
compar
oelvg
mut
oelv
immun
anim
fig
therapeut
potenti
elv
vaccin
analyz
tumor
reject
model
immun
anim
inocul
melanoma
cell
stabli
express
ova
rate
tumor
growth
monitor
time
measur
volum
tumor
control
mice
immun
sova
tumor
rapidli
develop
within
week
challeng
contrast
tumor
growth
delay
group
anim
immun
elv
odna
vaccin
fig
rapid
tumor
growth
mice
immun
oelvg
challeng
cell
express
ova
confirm
specif
protect
immun
respons
fig
dc
potent
antigen
present
cell
specif
target
activ
might
advanc
vaccin
design
exosom
secret
tumor
cell
shown
stabl
safe
immunogen
vehicl
tumor
antigen
howev
function
requir
activ
matur
dc
present
studi
shown
incorpor
vsvg
exosomelik
vesicl
enhanc
uptak
present
exosomeassoci
antigen
also
provid
import
matur
signal
dc
known
vsvg
mediat
bind
viru
cell
surfac
effici
entri
target
cell
via
endocytosi
inde
although
control
exosom
effect
intern
freshli
isol
murin
splenic
dc
incorpor
fusogen
form
vsvg
improv
deliveri
elv
dc
fig
howev
stimul
immun
respons
rather
toler
antigen
intern
dc
accompani
innat
immun
system
signal
induc
phenotyp
function
matur
dc
protein
composit
exosom
report
immunostimulatori
effect
could
explain
phenotyp
activ
dc
control
elv
vitro
fig
anoth
plausibl
explan
may
xenogen
origin
vesicl
howev
similar
experi
human
monocytederiv
dc
degre
activ
also
observ
unpublish
observ
hand
unlik
vsvg
contain
elv
control
elv
fail
upregul
activ
marker
murin
bone
marrowderiv
dc
data
shown
stimul
product
splenic
dc
function
matur
fig
togeth
suggest
vsvg
contain
exosom
provid
matur
signal
immatur
fulli
matur
dc
molecular
mechan
signal
discuss
use
lentivir
vector
pseudotyp
vsvg
pichlmair
et
al
recent
show
murin
bone
marrowderiv
plasmacytoid
dc
could
activ
due
viruslik
particl
rather
due
specif
shape
structur
carri
residu
amount
plasmid
dna
act
agonist
although
could
detect
trace
amount
dsdna
elv
prepar
rang
ngml
mean
ngml
dsdna
present
elv
type
independ
coexpress
vsvg
within
cotransfect
experi
minor
differ
dsdna
content
found
sampl
contain
fusiogen
mutant
form
vsvg
data
shown
thu
result
consist
vsvg
trigger
signal
pathway
recent
describ
act
downstream
vitro
crosspresent
experi
hint
specif
fig
tumor
challeng
mice
immun
indic
vaccin
challeng
cell
week
second
immun
antigenspecif
control
mice
immun
oelvg
also
challeng
cell
express
ova
tumor
growth
monitor
daili
volum
determin
interv
b
histogram
repres
size
tumor
day
challeng
mean
two
independ
experi
standard
deviat
statist
signific
differ
p
control
sova
group
fusiondepend
mechan
vsvgmediat
enhanc
dc
stimulatori
activ
despit
stimul
dc
matur
vsvg
contain
elv
abl
stimul
crossprim
dc
coexpos
solubl
ova
elv
contain
ova
physic
coloc
vsvg
ova
protein
elv
seem
requir
vsvgmediat
enhanc
crosspresent
fig
parent
vsv
vsvg
pseudotyp
viral
vector
rout
viral
genet
materi
cytoplasm
phagosomalendolysosom
lowph
compart
known
altern
mhc
class
pathway
process
intern
protein
antigen
could
demonstr
low
dose
nh
cl
block
intravesicular
acidif
also
phagosomelysosom
fusion
strongli
inhibit
process
vsvg
contain
elv
time
blockad
classic
mhc
class
pathway
rather
ineffect
fig
suggest
main
part
vsvgdepend
crosspresent
ova
due
elv
intern
acid
endolysosom
compart
antigen
gain
access
retrograd
transport
pathway
mhc
class
present
interestingli
blander
medzhitov
propos
model
mhc
class
ii
present
depend
presenc
tlr
ligand
within
phagocytos
cargo
individu
phagosom
tlr
ligand
enhanc
kinet
fusion
reaction
endocyt
pathway
activ
hydrolyt
enzym
may
explain
ova
physic
associ
vsvg
shuttl
altern
mhc
class
pathway
instead
termin
degrad
lysosom
vivo
vsvg
report
stimul
immun
respons
coadminist
antigen
previous
demonstr
vsvg
incorpor
hivbas
virallik
particl
enhanc
humor
cellular
immun
respons
hivgag
time
attempt
incorpor
vsvg
exosom
vaccin
contain
protein
sarscov
significantli
increas
immun
respons
sarss
sinc
protein
fusioncompet
transmembran
glycoprotein
immunostimulatori
effect
vsvg
might
mask
fusion
activ
sarss
present
studi
therefor
use
recombin
ova
protein
membranebound
model
antigen
character
immunostimulatori
properti
vsvg
context
elv
vaccin
immun
elv
contain
ova
lack
fusioncompet
vsvg
stimul
antibodi
product
suggest
thelper
cell
type
immun
respons
increas
level
observ
immun
oelvg
consist
induct
releas
dc
stimul
vitro
vsvg
contain
elv
fig
increas
frequenc
cytolyt
activ
cell
specif
exosom
antigen
support
conclus
vsvg
enhanc
respons
induc
elv
fig
b
although
elv
exogen
protein
vaccin
stimul
substanti
cell
respons
frequenc
ovaspecif
cell
induc
oelvg
even
higher
convent
dna
immun
fig
tumor
challeng
experi
group
mice
immun
elv
protect
independ
presenc
absenc
fusioncompet
vsvg
like
ctl
respons
induc
elv
absenc
vsvg
alreadi
suffici
control
growth
aggress
tumor
cell
therebi
mask
potenti
enhanc
protect
incorpor
vsvg
cell
known
express
low
level
mhc
class
fact
immun
mice
abl
control
tumor
growth
impli
high
avid
ctl
gener
taken
togeth
demonstr
coexpress
vsvg
antigen
surfac
exosom
modul
dc
activ
fusiondepend
manner
enhanc
dc
costimulatori
function
upregul
induct
dc
effector
function
product
acceler
antigen
intern
present
mhc
class
altern
pathway
involv
acid
endolysosom
vivo
studi
demonstr
effici
antigenspecif
cytotox
cell
respons
thu
present
studi
serv
proof
concept
use
vsvg
enhanc
immunogen
exosom
vaccin
time
studi
provid
gener
approach
tether
nonexosom
antigen
exosom
fuse
antigen
transmembran
intracytoplasm
domain
vsvg
could
offer
number
advantag
current
strategi
exosomebas
vaccin
test
primarili
cancer
field
target
select
tumor
antigen
exosom
genebas
immun
strategi
could
also
exploit
develop
vaccin
intracellular
parasit
virus
incorpor
microbi
antigen
vsvg
contain
elv
europris
grant
european
commiss
thank
dr
thoma
grunwald
depart
molecular
medic
virolog
ruhr
univers
bochum
germani
contribut
character
exosom
